| Literature DB >> 35537364 |
Premnath Madanagopal1, Harshini Muthukumar1, Kothai Thiruvengadam2.
Abstract
SARS-CoV-2 is a highly transmissible and pathogenic coronavirus that first emerged in late 2019 and has since triggered a pandemic of acute respiratory disease named COVID-19 which poses a significant threat to all public health institutions in the absence of specific antiviral treatment. Since the outbreak began in March 2020, India has reported 4.77 lakh Coronavirus deaths, according to the World Health Organization (WHO). The innate RNA interference (RNAi) pathway, on the other hand, allows for the development of nucleic acid-based antiviral drugs in which complementary small interfering RNAs (siRNAs) mediate the post-transcriptional gene silencing (PTGS) of target mRNA. Therefore, in this current study, the potential of RNAi was harnessed to construct siRNA molecules that target the consensus regions of specific structural proteins associated genes of SARS-CoV-2, such as the envelope protein gene (E), membrane protein gene (M), nucleocapsid phosphoprotein gene (N), and surface glycoprotein gene (S) which are important for the viral pathogenesis. Conserved sequences of 811 SARS-CoV-2 strains from around India were collected to design 21 nucleotides long siRNA duplex based on various computational algorithms and parameters targeting E, M, N and S genes. The proposed siRNA molecules possessed sufficient nucleotide-based and other features for effective gene silencing and BLAST results revealed that siRNAs' targets have no significant matches across the whole human genome. Hence, siRNAs were found to have no off-target effects on the genome, ruling out the possibility of off-target silencing. Finally, out of 157 computationally identified siRNAs, only 4 effective siRNA molecules were selected for each target gene which is proposed to exert the best action based on GC content, free energy of folding, free energy of binding, melting temperature, heat capacity and molecular docking analysis with Human AGO2 protein. Our engineered siRNA candidates could be used as a genome-level therapeutic treatment against various sequenced SARS-CoV-2 strains in India. However, future applications will necessitate additional validations in vitro and in vivo animal models.Entities:
Keywords: COVID-19; Docking; Gene silencing; RNA interference; SiRNA
Mesh:
Substances:
Year: 2022 PMID: 35537364 PMCID: PMC9052778 DOI: 10.1016/j.compbiolchem.2022.107687
Source DB: PubMed Journal: Comput Biol Chem ISSN: 1476-9271 Impact factor: 3.737
Fig. 1Graphical representation of the siRNA-mediated gene silencing mechanism (MMAK et al., 2021).
Fig. 2Flowchart depicting the workflow of the methodology used in the study.
Rules/Algorithms for designing of effective siRNA molecules.
| Ui-Tei rules | Amarzguioui rules | Reynolds rules |
|---|---|---|
A/U at the 5′ end of the antisense strand G/C at the 5′ end of the sense strand At least five A/U residues in the 5′ terminal one‐third of the antisense strand The absence of any GC stretches of more than 9 nt in length | The A/U differential of the duplex end should be > 0 Strong binding of 5 sense strand Position 1 must have any bases other than U Position 6 must have A constantly Weak attachment of 3′ sense/passenger strand. | The designed siRNA must maintain a GC content between 30% and 52% (1 point) Occurrence of three or more A/U base pair at position 15–19 of sense strand (Each A/U base pair in this region earns one point) The Tm (melting temperature) of designed siRNA must be greater than − 20 °C (1 point) Position 19 of sense strand must contain A (1 point) Position 3 of sense strand must include A (1 point) Position 10 of the sense strand should have U (1 point) Position 13 of the sense strand must contain any bases other than G (1 point) Threshold for efficient siRNAs score≥ 6 |
Effective siRNA molecules with GC%, free energy of folding and free energy of binding with target.
| S.no | Alias | Conserved position | Location of target within mRNA | siRNA target within mRNA | Predicted siRNA duplex candidate at 37◦C; RNA oligo sequences 21nt guide (5′ →3′) 21nt passenger (5′ →3′) | Functional siRNA selection: Ui-Tei (U), Reynolds (R) and Amarzguioui (A) | Seed duplex (Tm) guide °C | Seed duplex (Tm) Passenger °C | GC% | Free energy of folding (kcal/mol) | Free energy of binding (kcal/mol) | Tm (Conc) °C | Tm (Cp) °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | e5 | 70–95 | 1–23 | GTGGTATTCTTGCTAGTTACACT | UGUAACUAGCAAGAAUACCAC | 14.3 | 14.5 | 38% | 1.7 | -34.1 | 85 | 86 | |
| 2 | m1 | 16–83 | 9–31 | TACCGTTGAAGAGCTTAAAAAGC | UUUUUAAGCUCUUCAACGGUA | -3.8 | 21.1 | 38% | 1.8 | -31.3 | 87.5 | 88.7 | |
| 3 | m2 | 16–83 | 21–43 | GCTTAAAAAGCTCCTTGAACAAT | UGUUCAAGGAGCUUUUUAAGC | 19.2 | -3.8 | 33% | 1.6 | -33.5 | 86.3 | 86.9 | |
| 4 | n1 | 717–749 | 11–33 | GGCCAAACTGTCACTAAGAAATC | UUUCUUAGUGACAGUUUGGCC | 11.7 | 16.7 | 40% | 1.8 | -35.8 | 86.2 | 87.6 | |
| 5 | n2 | 809–860 | 27–49 | CCAGAACAAACCCAAGGAAATTT | AUUUCCUUGGGUUUGUUCUGG | 18.7 | 14.9 | 38% | 1.7 | -34.9 | 88.9 | 90.3 | |
| 6 | g36 | 919–1022 | 38–60 | GCCCTTTTGGTACTGTAGAAAAA | UUUCUACAGUACCAAAAGGGC | 20.3 | 16.1 | 38% | 1.9 | -36.1 | 88.9 | 89.3 | |
| 7 | g82 | 1964–2024 | 39–61 | GCAGGTATATGCGCTAGTTATCA | AUAACUAGCGCAUAUACCUGC | 11.3 | 15.2 | 40% | 1.8 | -35.7 | 87.4 | 88.2 | |
| 8 | g83 | 2194–2339 | 1–23 | ACCAAGACATCAGTAGATTGTAC | ACAAUCUACUGAUGUCUUGGU | 13.4 | 19.2 | 38% | 1.5 | -34.9 | 83.5 | 84.7 | |
| 9 | g105 | 2676–2720 | 19–41 | TGCTATGCAAATGGCTTATAGGT | CUAUAAGCCAUUUGCAUAGCA | 14.9 | 21.1 | 38% | 1.5 | -34.8 | 85.1 | 86.0 | |
| 10 | g134 | 3649–3713 | 18–40 | TGGCTTGATTGCCATAGTAATGG | AUUACUAUGGCAAUCAAGCCA | 6.3 | 12.0 | 40% | 2 | -34.8 | 86.1 | 87.1 | |
| 11 | g80 | 1881–1925 | 9–31 | CTCCTACTTGGCGTGTTTATTCT | AAUAAACACGCCAAGUAGGAG | 6.9 | 16.4 | 43% | 1.9 | -34.7 | 89.7 | 91.0 | |
| 12 | g109 | 2722–2785 | 14–36 | CACAGAATGTTCTCTATGAGAAC | UCUCAUAGAGAACAUUCUGUG | 17.8 | 19.2 | 38% | 1.9 | -34.7 | 84.4 | 84.0 |
Fig. 3The cartoon representation of the structure of Human Argonaute 2 (Ago2) protein.
siRNAs docking score and interaction statistics.
| S.no | siRNA in Ago2-siRNA complex | HDock Docking score | Interaction Category | Total number of interacting residues | |||
|---|---|---|---|---|---|---|---|
| Salt bridge (Hydrogen Bond+Electrostatic) | Hydrogen bonds | Electrostatic bonds | Hydrophobic bonds | ||||
| 1 | e5 | -322.34 | 7 | 16 | 8 | 5 | 23 |
| 2 | m1 | -324.56 | 3 | 13 | 11 | 6 | 27 |
| 3 | m2 | -348.34 | 3 | 15 | 8 | 3 | 20 |
| 4 | n1 | -335.64 | 1 | 15 | 7 | 0 | 16 |
| 5 | n2 | -294.72 | 1 | 10 | 9 | 5 | 14 |
| 6 | g36 | -354.19 | 1 | 12 | 7 | 2 | 16 |
| 7 | g82 | -290.15 | 1 | 21 | 10 | 3 | 19 |
| 8 | g83 | -326.1 | 1 | 12 | 4 | 5 | 12 |
| 9 | g105 | -312.45 | 2 | 14 | 3 | 3 | 17 |
| 10 | g134 | -338.34 | 0 | 14 | 3 | 2 | 12 |
| 11 | g80 | -358.89 | 4 | 8 | 10 | 2 | 17 |
| 12 | g109 | -319.69 | 3 | 12 | 7 | 2 | 12 |
Fig. 4The possible folding and minimum free energy of the guide strands of the predicted siRNA molecules. The structures are for A. e5 B. m1 C. m2 D. n1 E. n2 F. g36 G. g82 H. g83 I. g105 J. g134 K. g80 L. g109 siRNAs.
Fig. 5Structure of binding of target RNA and siRNA (guide strand) with corresponding predicted minimum free energy. The structures are for A. e5 B. m1 C. m2 D. n1 E. n2 F. g36 G. g82 H. g83 I. g105 J. g134 K. g80 L. g109 siRNAs.
Final siRNA candidates with respect to each gene.
| S.no | Alias | Predicted siRNA siRNA duplex candidate at 37◦C; RNA oligo sequences 21nt guide (5′ →3′) 21nt passenger (5′ →3′) | Functional siRNA selection: Ui-Tei (U), Reynolds (R) and Amarzguioui (A) | Seed duplex (Tm) guide °C | Seed duplex (Tm) Passenger °C | GC% | Free energy of folding (kcal/mol) | Free energy of binding (kcal/mol) | HDock Docking score |
|---|---|---|---|---|---|---|---|---|---|
| 1 | e5 | UGUAACUAGCAAGAAUACCAC | 14.3 | 14.5 | 38% | 1.7 | -34.1 | -322.34 | |
| 2 | m2 | UGUUCAAGGAGCUUUUUAAGC | 19.2 | -3.8 | 33% | 1.6 | -33.5 | -348.34 | |
| 3 | n1 | UUUCUUAGUGACAGUUUGGCC | 11.7 | 16.7 | 40% | 1.8 | -35.8 | -335.64 | |
| 4 | g80 | AAUAAACACGCCAAGUAGGAG | 6.9 | 16.4 | 43% | 1.9 | -34.7 | -358.89 |
Fig. 6Docked structures of final siRNA candidates (cartoon view) with Human Ago2 protein (surface view) along with 3D interaction of docking analysis. The PAZ domain and the MID domain are coloured magenta and cyan respectively and the rest of the protein is denoted by orange colour (including the N-terminal domain and PIWI domain). The siRNA was designated by yellow colour. The structures are for A. e5 B. m2 C. n1 D. g80 siRNAs.